CN108017604B - Alpha-acid derivative and preparation method and application thereof - Google Patents

Alpha-acid derivative and preparation method and application thereof Download PDF

Info

Publication number
CN108017604B
CN108017604B CN201610944141.8A CN201610944141A CN108017604B CN 108017604 B CN108017604 B CN 108017604B CN 201610944141 A CN201610944141 A CN 201610944141A CN 108017604 B CN108017604 B CN 108017604B
Authority
CN
China
Prior art keywords
mixed solvent
water
methanol
compound
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610944141.8A
Other languages
Chinese (zh)
Other versions
CN108017604A (en
Inventor
李宁
魏秀岩
侯悦
陈刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CN201610944141.8A priority Critical patent/CN108017604B/en
Priority to CN202110396943.0A priority patent/CN113149944B/en
Publication of CN108017604A publication Critical patent/CN108017604A/en
Application granted granted Critical
Publication of CN108017604B publication Critical patent/CN108017604B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a novel alpha-acid derivative, a preparation method thereof and application thereof in the field of preparing medicaments for preventing or treating liver injury and neurodegenerative diseases, in particular to novel alpha-acid derivatives 1-14 and preparation and application thereof.

Description

Alpha-acid derivative and preparation method and application thereof
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a novel alpha-acid derivative, and a preparation method and application thereof.
Background
Humulus lupulus L, also called Chinese hop, lupulus, is sweet and bitter in taste and mild in nature. Is perennial herb vine, female and male heterostrain, unisexual flower, female bulb inflorescence, abbreviated as hops of Humulus of Moraceae. It is a cold-resistant and heat-labile plant, and is mainly distributed in northwest region of China, northern Xinjiang, northeast, east China, Shandong, Gansu, Shaanxi, etc. At present, the hop yield in China accounts for about 13 percent of the world, is second only to the United states and Germany, and is third in the world.
The hop is one of the main raw materials for brewing beer, can endow the beer with special bitter taste and unique flavor, enhances the non-biostability and the bubble persistence of the beer, has certain anti-corrosion performance, and is known as the 'soul of the beer'. Besides being mainly used for brewing beer, the application history of the hop serving as an important medicinal plant is long. Beginning in the 13 th century, hops began to be used as herbal medicines. The hop is one of the Chinese traditional medicine dao de hua in Song Dynasty 'Kaibao' from Ben Cao gang mu of Li Shizhen in Ming Dynasty of China. Hops are reported to be useful for antisepsis, stomach strengthening, nerve calming, hypnosis, disinfection, anti-inflammation, and diuresis, and also for the treatment of dyspepsia, insomnia, tuberculosis, leprosy, and the like.
In recent years, pharmacological actions on hop extracts or compounds contained therein have been focused on antibacterial, antioxidant, sedative and estrogen-like actions. The hop has various chemical components, and takes flavonoid, resin (alpha-acid and beta-acid) and volatile oil compounds as chemical characteristics, wherein the resin components have obvious biological activity and are the main representatives of the medicinal components of the hop. Because the polarity difference of the alpha-acid component is small and the stereochemistry problem is complex, the separation and purification, the structure identification and the evaluation of the pharmacological activity of the monomer compound and the development of new drugs are difficult to perform.
The patent provides a method for preparing novel alpha-acid derivatives from hops and illustrates the medical application of the novel alpha-acid derivatives in the aspects of liver protection and neuritis resistance.
Disclosure of Invention
The invention aims to provide a novel alpha-acid derivative, a preparation method and a novel medical application thereof.
The present invention provides novel alpha-acid derivatives having the following structure.
Figure BDA0001140421780000011
R1Is C1-C4 alkyl, R2，R3，R4Is hydrogen or C1-C4 alkyl;
preferably, R1Is methyl, ethyl, propyl, isopropyl, n-butyl, 2-methylpropyl, 1, 1-dimethylethyl;
R2，R3，R4is methyl, ethyl, propyl, isopropyl, n-butyl, 2-methylpropyl, 1, 1-dimethylethyl.
Further, the following derivatives are preferred in the present invention:
Figure BDA0001140421780000021
the present invention also provides a method for preparing the novel alpha-acid derivatives 1 to 14, which comprises the following steps:
(1) extracting female inflorescence of flos Lupuli (Humulus lupulus L.) with ethanol, and recovering extractive solution to obtain crude extract;
(2) separating the crude extract obtained in the step (1) by silica gel column chromatography, and performing gradient elution by using a mixed solvent of petroleum ether and ethyl acetate, or using a mixed solvent of petroleum ether and acetone, or a mixed solvent of chloroform and acetone, or dichloromethane and acetone, or chloroform and methanol, or a mixed solvent of dichloromethane and methanol;
(3) performing ODS (ODS chromatography) separation on the fraction obtained in the step (2) at a ratio of 100: 1-100: 25, and performing gradient elution by using a mixed solvent of methanol and water as a mobile phase, or performing gradient elution by using a mixed solvent of acetonitrile and water as a mobile phase;
(4) and (3) further separating the fraction 1: 9-7: 3 obtained in the step (3) by HPLC-RID10A, and performing gradient elution by using a mixed solvent of methanol and water as a mobile phase or using a mixed solvent of acetonitrile and water as a mobile phase to obtain a racemic mixture of alpha-acids 1-7,9 and 10 and a racemic mixture of 11 and 12.
(5) And (3) repeatedly recrystallizing the fraction 1: 9-7: 3 obtained in the step (3) to obtain a new alpha-acid derivative 8 and a racemic mixture of 13 and 14.
(6) And (3) carrying out HPLC chiral resolution on the racemic mixture of the novel alpha- acid derivatives 9 and 10, the racemic mixture of 11 and 12 and the racemic mixture of 13 and 14 obtained in the steps (4) and (5), and taking a mixed solvent of n-hexane and ethanol as a resolution solvent to obtain the novel alpha- acid derivatives 9,10,11,12,13 and 14.
The hop is the female inflorescence of hop of a Humulus (Humulus) plant of the genus Humulus of the family Moraceae (Moraceae).
The invention provides a preparation method of the novel alpha-acid derivatives 1-14, the extraction method in the step (1) is heating reflux extraction or heating ultrasonic extraction for 1-3 times, the used solvent is 50-100% ethanol, and the medicinal materials: the weight-volume ratio of the solvent is 1: 5-1: 25.
According to the preparation method of the novel alpha-acid derivatives 1-14 provided by the invention, the proportion of the mixed solvent of petroleum ether and ethyl acetate in the step (2) is 100: 1-1: 1, preferably 100: 6-4: 1, or the ratio of the mixed solvent of petroleum ether and acetone is 100: 1-1: 1, preferably 100: 3-100: 5, or the ratio of chloroform to acetone or dichloromethane to acetone mixed solvent is 100: 1-100: 20, preferably 100: 2-100: 15, or the ratio of the mixed solvent of chloroform and methanol or the mixed solvent of dichloromethane and methanol in gradient elution is 100: 1-100: 20, preferably 100:1 to 10: 1.
According to the preparation method of the novel alpha-acid derivatives 1-14 provided by the invention, in the step (3), the methanol and water mixed solvent is prepared, wherein the ratio of the mixed solvent is 2: 8-9: 1, preferably 4: 6-7: 3 or a mixed solvent of acetonitrile and water, wherein the ratio of the mixed solvent is 1: 9-7: 3, preferably 1: 9-1: 1.
according to the preparation method of the novel alpha-acid derivative 1-14, in the step (4), the ratio of the mobile phase methanol to the water mixed solvent is 1: 1-8: 2, preferably 6: 4-7: 3, and the ratio of the acetonitrile to the water mixed solvent is 3: 7-1: 1, preferably 4: 6-1: 1.
According to the preparation method of the novel alpha-acid derivatives 1-14 provided by the invention, the volume ratio of the mixed solvent of methanol and water in the step (5) is as follows: 6: 4-9: 1, preferably 6: 4-8: 2, the volume ratio of the acetonitrile-water mixed solvent is 2: 8-7: 3, preferably 2: 8-4: 6.
according to the preparation method of the novel alpha-acid derivatives 1-14 provided by the invention, in the step (6), the volume ratio of the eluent used for HPLC chiral column resolution to the mixed solvent of n-hexane and ethanol is as follows: 90:10 to 95:5, preferably 93:7 to 95: 5.
The invention uses H2O2The prepared novel alpha-acid derivative 1-14 is evaluated in the liver protection and anti-neuritis activity of an induced HePG2 and L-02 liver cell oxidative damage model and an LPS induced BV2 microglia over-activation model. The results show that the novel compounds 2, 8, 9,10,11,12,13 and 14 can remarkably protect H2O2Causing oxidative damage to HepG2 and L-02 hepatocytes, compound 7 had moderate-intensity hepatocyte protective activity. The novel alpha- acid derivatives 1,9, 10,11,12,13,14 (30 mu M, 100 mu M), 3, 5, 7(100 mu M) can remarkably inhibit LPS-induced release of excessive activated BV2 microglia NO, and show remarkable anti-neuritic activity. Therefore, the novel alpha-acid compound prepared by the invention can be applied to the development of medicaments for protecting liver and treating neurodegenerative diseases.
The invention provides a method for preparing and identifying 14 new alpha-acid derivatives by taking hops as raw materials for the first time, systematically evaluates the activity of the derivatives in liver protection and neuroprotection, and clarifies the application of the derivatives in developing medicaments for liver protection and treating neurodegenerative diseases.
Drawings
FIG. 1 shows the different compound pairs H2O2The effect of impaired HepG2 survival;
FIG. 2 shows the different compounds in pair H2O2Protection rate of damaged HepG2 cells;
FIG. 3 shows different pairs of compounds H2O2Effect of impaired L-02 survival;
FIG. 4 shows different compound pairs H2O2Protective rate of injured L-02 cells.
Detailed Description
The following examples further illustrate the invention but are not intended to limit the invention thereto.
Example 1
(1) Extracting 900g flos Lupuli with 50% ethanol under reflux for 1 time (dosage: 22.5L), and recovering extractive solution under reduced pressure to obtain crude extract;
(2) separating the ethanol extract obtained in the step (1) by silica gel column chromatography, and sequentially adding petroleum ether: ethyl acetate 100:1, 100:3,100:6,100: 8, 8:1, 7:1, 2:1, 1: 1;
(3) the petroleum ether obtained in the step (2): the ethyl acetate 100:6 stream was subjected to ODS chromatography with a methanol/water 2:8,4: gradient elution with mobile phase of 6,1:1,6:4, 9: 1;
(4) the methanol obtained in the step (3): the water (6: 4) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (7:3) as mobile phase to obtain racemic mixture (t) of new alpha-acid, compound 9 and 10RYield 0.012% over 45min, compound 4 (t)R60min) (yield 0.048%). The racemic mixture of compounds 9 and 10 was further separated by chiral column chromatography using n-hexane: elution with ethanol (95:5) as the mobile phase yielded new alpha-acids 9(10.565min),10(12.826min) (0.006% yield each).
(5) The methanol obtained in the step (3): water (1:1) fraction through the crystallization solvent methanol: water (9:1) was repeatedly recrystallized to obtain a racemic mixture of compounds 13 and 14 (yield 0.043%). The racemic mixture of compounds 13 and 14 was further separated by chiral column chromatography using n-hexane: elution with ethanol (95:5) as the mobile phase yielded new alpha-acids 13(7.220min),14(9.597min) (0.021% yield each).
(6) The petroleum ether obtained in the step (2): the ethyl acetate 100:8 stream was subjected to ODS chromatography with methanol/water 4: and 6,1:1,6:4 is mobile phase gradient elution.
(7) The methanol obtained in the step (6): the water (1:1) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (7:3) as mobile phase to obtain new alpha-acid, compound 1 (t)R50min) (yield 0.077%) and compound 5 (t)R64min) (yield 0.099%).
(8) The petroleum ether obtained in the step (2): the ethyl acetate 8:1 stream was separated by ODS chromatography in methanol/water 4:6,1:1,6:4 is mobile phase gradient elution;
(9) the methanol obtained in the step (8): the water (1:1) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (8:2) as mobile phase to obtain new alpha-acid, compound 7 (t)R60min) (yield 0.028%).
(10) The petroleum ether obtained in the step (2): the ethyl acetate 7:1 stream was separated by ODS chromatography in methanol/water 4:6,1:1,6:4 is mobile phase gradient elution;
(11) the methanol obtained in the step (10): the water (6: 4) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (72: 28) as mobile phase to obtain new alpha-acid, compound 2 (t)R48min, yield 0.016%), compound 3 (t)RYield 0.042% 59min, compound 6 (t)R35min, yield 0.017%), racemic mixture of compounds 11 and 12 (t ═ t)R65min, yield 0.010%). The racemic mixture of compounds 11 and 12 was further separated by chiral column chromatography using n-hexane: elution with ethanol (95:5) as the mobile phase yielded new alpha-acids 11(9.958min),12(11.304min) (0.005% yield each).
(12) The petroleum ether obtained in the step (2): the ethyl acetate 4:1 stream was chromatographed on an ODS column using a methanol/water 2:8,4: gradient elution with mobile phase of 6,1:1,6:4, 9: 1;
(13) the methanol obtained in the step (12): water (1:1) fraction through the crystallization solvent methanol: water (8:2), repeated recrystallization techniques to give the novel alpha-acid, compound 8 (yield 0.043%).
The structures of compounds 1-14 were identified based on their physicochemical properties and spectral data.
The structural identification data of the compound 1 (3R,8S) -humulone A are as follows:
Figure BDA0001140421780000041
a pale yellow oily solid (dichloromethane),
Figure BDA0001140421780000042
87.0(c 13.8 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:401.1950(calcd.401.1935 for C21H30NaO6) It can be seen that the molecular formula is C21H30O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 1.
The connection mode of each fragment is determined by HMBC. In HMBC spectra, δH2.83(1H, dd, J ═ 13.8,6.6Hz, H-2"a),2.79(1H, dd, J ═ 13.8,7.4Hz, H-2" b) are remotely related to 200.9(C-1"), so the isobutyl group is attached to the carbonyl; by deltaH18.84(5-OH) and 200.9 (C-1') to obtain isovaleryl directly connected with alpha-acids mother nucleus; deltaH2.59(1H, dd, J ═ 13.8,6.6Hz, H-1 '"a), 2.50(1H, dd, J ═ 13.8,7.4Hz, H-1'" b) are remotely related to 77.5(C-5),167.4(C-8a),195.5(C-7), further illustrating that α -acids4 position isopentenyl and 5 position hydroxyl are cyclized to form pyran ring. DeltaH3.81(1H, t, J ═ 4.7Hz, H-3) correlates with 101.7(C-4a), δH2.56(2H, d, J ═ 4.7Hz, H-4) correlates with 68.3(C-3),81.8(C-2),101.7(C-4a), from which the presence of the pyran ring can be determined.
The relative configuration of compound 1 was determined by NOESY. In the NOESY spectrum, δH3.81(H-3) and 2.56(H-4),1.37(2' -CH)3) Correlation; deltaH 1.43(2'-CH3) And 5.01(H-2 '), 1.66 (4' -CH)3) Correlation; from this, isopentenyl group and 1' -CH can be presumed3On the same side as 2' -CH3On the opposite side.
The absolute configuration of the compound is determined by ECD calculation by using a TDDFT (time density functional theory) method, and the spectrum measured by an experiment is compared with the ECD spectrum of which the calculated enantiomer is (3R,8S), and the spectrum is matched, wherein the result shows that positive Compton effect (Cotton effect) exists in the regions of 210nm and 320nm of 205-. Thus, the absolute configuration of the compound was determined to be 3R, 8S.
TABLE 1 attribution of NMR data on Compound 1
Figure BDA0001140421780000051
The structural identification data of compound 2 (3S,8S) -humulone A are as follows:
Figure BDA0001140421780000061
a pale yellow oily solid (dichloromethane),
Figure BDA0001140421780000062
50.9(c 1.15 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:401.1933(calcd.401.1935 for C21H30NaO6) It can be seen that the molecular formula is C21H30O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 2.
The manner of ligation of the individual fragments was determined by HMBC spectroscopy. In HMBC spectra, δH2.86-2.77(2H, m, H-2 ') and 200.7 (C-1') remote, so isobutyl is attached to the carbonyl; deltaH18.79(5-OH) correlates with 200.7 (C-1') suggesting that isovaleryl is directly linked to the alpha-acids mother nucleus; deltaH2.58(1H, dd, J ═ 13.8,7.8Hz, H-1 "'a), 2.46(1H, dd, J ═ 13.8,7.6Hz, H-1"' b) and 77.6(C-8),167.2(C-8a),195.5(C-7) remote phasesAnd further illustrates that the pyran ring is synthesized by the isopentenyl group at the 4-position and the hydroxyl group at the 5-position of the alpha-acids. DeltaH3.76(1H, t, J ═ 5.4Hz, H-3) associated with 81.6(C-2),102.2(C-4a), δH2.74(1H, dd, J ═ 17.5,5.0Hz, H-4a),2.35(1H, dd,17.5,5.9Hz, H-4b) correlated with 69.0(C-3),81.6(C-2),102.2(C-4a), and the presence of the pyran ring could be determined.
The relative configuration of compound 2 was determined by means of NOESY spectroscopy. In the NOESY spectra, 3.76(H-3) was compared with 2.74(H-4a),4.95(H-2 '),1.37(2' -CH)3) Correlation; 2.35(H-4b) and 1.42(1' -CH)3) Correlation; 2.74(H-4a) and 3.76(H-3),1.37(2' -CH)3) And (4) correlating. The isopentenyl group is known to be associated with H-3,2' -CH3On the same side as 1' -CH3On the opposite side.
The absolute configuration of the compound is determined by comparing the CD spectrum with that of the compound 1, and both the CD spectrum and the CD spectrum are negative Comton effect (Cotton effect) between 260-380, which is caused by alpha, beta unsaturated ketone groups, thereby determining that the 8-position configuration of the compound 2 is the same as the 8-position configuration of the compound 1, and both the CD spectrum and the CD spectrum are S configuration. The difference between the CD spectra of the two compounds is that the 190-200nm wavelength band is linear, which is probably caused by the difference between the absolute configuration of the 3-position of the compound 1 and the absolute configuration of the compound 2, so the absolute configuration of the compound 2 is primarily determined as (3S,8S), and the absolute configuration of the 3-position of the compound 2 can be further determined as the 3S configuration by NOE, thereby confirming the ECD calculation result. Thus, the absolute configuration of the compound was determined to be 3S, 8S.
TABLE 2 NMR data assignment for Compound 2
Figure BDA0001140421780000063
Figure BDA0001140421780000071
The structural identification data of the compound 3 (3S,8S) -cohumulone A are as follows:
Figure BDA0001140421780000072
a light yellow oil (dichloromethane),
Figure BDA0001140421780000073
23.2(c 4.20 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:387.1776(calcd.387.1778 for C20H28NaO6) It can be seen that the molecular formula is C20H28O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 3.
The manner of ligation of the individual fragments was determined by HMBC spectroscopy. In HMBC spectra, δH3.74(1H, m, H-2 ') is remotely related to 205.7 (C-1'), so the isopropyl group is attached to the carbonyl group; by deltaH18.92(5-OH) correlates with 205.7 (C-1'), then isobutyryl is directly attached to the α -acids parent nucleus; deltaH2.59(1H, dd, J ═ 13.8,7.7Hz, H-1 '"a), 2.46(1H, dd, J ═ 13.8,7.9Hz, H-1'" b) are remotely related to 77.7(C-8),167.2(C-8a),195.4(C-7), further illustrating that the isopentenyl group at the 4-position of alpha-acids and the hydroxyl group at the 5-position are cyclized to form a pyran ring. DeltaH3.76(1H, m, H-3) is related to 81.6(C-2),102.0(C-4a), ΔH2.71(1H, dd, J ═ 17.5,4.9Hz, H-4a),2.36(1H, dd, J ═ 17.5,5.7Hz, H-4b) correlated with 69.0(C-3),81.6(C-2),102.0(C-4a), from which the presence of the pyran ring could be determined.
The relative configuration of compound 3 was determined by means of NOESY spectroscopy. In the NOESY spectra, 3.76(H-3) was compared with 2.71(H-4a),4.96(H-2 '"), 1.38(2' -CH)3) Correlation; 2.36(H-4b) and 1.42(1' -CH)3) And (4) correlation; 2.71(H-4a) and 3.76(H-3),1.38(2' -CH)3) Related to this, isopentenyl is known to be associated with H-3,2' -CH3On the same side as 1' -CH3On the opposite side.
The absolute configuration of the compound was determined by comparing the CD spectrum with that of the compound 2, both having positive Comton effect (Cotton effect) in the regions of 195-215nm and 260-330nm, negative Comton effect in the regions of 220-260nm and 350-400nm, and the CD spectra were linearly similar between 195-215nm, so that the absolute configuration of the compound 3 was preliminarily determined to be (3S, 8S). And because the CD spectra of the compound 3 and the compound 2 are compared, the Cotton effect between 260-380 is the same, which is caused by alpha and beta unsaturated ketone groups, the 8-position of the compound 3 and the 8-position of the compound 2 can be determined to be the same and are both S-configurations, the 3-position absolute configuration of the compound 3 can be further determined to be 3S-configuration by NOE, and the result of ECD calculation is further confirmed, so that the absolute configuration of the compound 3 is finally determined to be (3S, 8S).
TABLE 3 NMR data assignment for Compound 3
Figure BDA0001140421780000081
The structural identification data of compound 4 (2S,7S) -humulone B are as follows:
Figure BDA0001140421780000082
a reddish-brown oil (dichloromethane),
Figure BDA0001140421780000083
41.7(c 1.2 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:401.1937(calcd.401.1935 for C21H30NaO6) It can be seen that the molecular formula is C21H30O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 4.
The manner of ligation of the individual fragments was determined by HMBC spectroscopy. In HMBC spectra, δH2.82(1H, dd, J ═ 13.8,6.8Hz),2.76(1H, dd, J ═ 13.8,7.5Hz) is associated with 199.7(C-1") remote, so isobutyl is attached to the carbonyl; deltaH18.50(4-OH) correlates with 199.7 (C-1') suggesting that isovaleryl is directly linked to the alpha-acids mother nucleus; deltaH2.62(1H, dd, J ═ 14.1,8.7Hz, H-2"a),2.43(1H, dd, J ═ 14.1,5.7Hz, H-2" b) and δC76.2(C-7),173.1(C-7a),196.1(C-6) are related remotely, further illustrating that the 4-isopentenyl group of the alpha-acids and the 5-hydroxyl group are cyclized to form a five-membered ring.
The relative configuration of Compound 4 was followed by NOESY spectroscopyIt was determined that, in the NOESY spectrum: 4.84(H-2) is strongly correlated with 2.90(H-3b) and weakly correlated with 3.00(H-3 a); 5.23(H-2 ') and 1.37(2' -CH)3) While there was some correlation, it was found that H-2 was the same as H-3b, and H-3a was the same as 2-tert-propanol and 7-isopentenyl group, although there was no correlation with 4.84 (H-2).
The absolute configuration of the compound is determined by ECD calculation by using a TDDFT (time density functional theory) method, the spectrum measured by an experiment is compared with the ECD spectrum of (2S,7S) obtained by calculation, the two spectra are matched, and the positive Compton effect (Cotton effect) exists in the regions of 190-200nm and 260-325nm, and the negative Compton effect exists in the regions of 210-250nm and 330-370 nm. Thus, the absolute configuration of the compound was determined to be (2S, 7S).
TABLE 4 NMR data assignment for Compound 4
Figure BDA0001140421780000091
Figure BDA0001140421780000101
The structural identification data of compound 5 (2R,7S) -humulone B are as follows:
Figure BDA0001140421780000102
a reddish-brown oil (dichloromethane),
Figure BDA0001140421780000103
54.0(c 4.15 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:401.1950(calcd.401.1935 for C21H30NaO6) It can be seen that the molecular formula is C21H30O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 5.
The manner of ligation of the individual fragments was determined by HMBC spectroscopy. In HMBC spectra, δH 2.81(1H, dd, J13.7, 7.5Hz, H-2"a),2.76(1H, dd, J13.7, 6.7Hz, H-2" b) is remotely related to 199.3(C-1"), so that the isobutyl group is attached to the carbonyl group; deltaH18.47(4-OH) is associated with 199.3 (C-1'), suggesting that isovaleryl is directly linked to the α -acids mother nucleus; deltaH2.56(2H, dd, J-7.5, 4.6Hz, H-2') and deltaC75.9(C-7),172.8(C-7a),196.0(C-6) remote correlation, further illustrate that the 4-position isopentenyl group and the 5-position hydroxyl group of the alpha-acids are cyclized to synthesize a five-membered furan ring.
The relative configuration of Compound 5 was determined by means of a NOESY spectrum in which 4.76(H-2) was strongly correlated with 2.93(H-3a) and weakly correlated with 2.88(H-3 b); 2.88(H-3b) and 1.37(2' -CH)3),1.17(3'-CH3) Of relevance, 1.65 (4' -CH)3) And 1.37(2' -CH)3),1.17(3'-CH3) It is found that H-2 is the same as H-3a and the isopentenyl group at the 7-position, and H-3b is the same as the tertiary propanol at the 2-position.
The absolute configuration of the compound 5 is determined by comparing with the measured CD spectrum and the ECD calculated spectrum of the compound 4, the two forms have the same Cotton effect between 260-380, which is caused by n-pi transition of alpha, beta unsaturated ketone bonds, thereby determining that the 7-position of the compound 5 and the 7-position of the compound 4 have the same configuration, both forms are S-configuration, the CD spectra are different in that the wavelength range between 190-210nm is positive Cotton effect, but the linear trend of CD curves is different, which is the CD curve difference caused by the opposite absolute configuration of the 2-position, so that the absolute configuration of the 2-position of the compound 5 is 2R. The 2-position configuration of compound 5 was further identified as 2R by NOESY spectrum, and thus the absolute configuration of the compound was determined to be (2R, 7S).
TABLE 5 NMR data assignment for Compound 5
Figure BDA0001140421780000104
Figure BDA0001140421780000111
The structural identification data of compound 6 (2R,7S) -cohumulone B is as follows:
Figure BDA0001140421780000112
a reddish-brown oil (dichloromethane),
Figure BDA0001140421780000113
11.0(c 1.60 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:387.1778(calcd.387.1778 for C20H28NaO6) It can be seen that the molecular formula is C20H28O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 6.
The manner of ligation of the individual fragments was determined by HMBC spectroscopy. In HMBC spectra, δH3.74(1H, m) is remotely related to 204.7, so the isopropyl group is attached to the carbonyl group; deltaH18.68 is related to 204.7 (C-1'), suggesting that isobutyryl is directly linked to the α -acids mother nucleus; deltaH2.63(1H, dd, J ═ 14.5,8.6Hz, H-2"a),2.43(1H, dd, J ═ 14.5,5.1Hz, H-2" b) are remotely related to 76.3(C-7),173.3(C-7a),196.0(C-6), further illustrating that the 4-position isopentenyl group and the 5-position hydroxyl group of the α -acid are cyclized to form a five-membered furan ring.
The relative configuration of Compound 6 was determined by NOESY Spectroscopy, in which the number of residues is given by deltaH4.84(H-2) is strongly correlated with 2.91(H-3b) and weakly correlated with 3.00(H-3 a); deltaH5.24(H-2 ') and 1.37(2' -CH)3) While there was some correlation, it was found that H-2 was the same as H-3b, and H-3a was the same as 2-tert-propanol and 7-isopentenyl group, although there was no correlation with 4.84 (H-2).
The absolute configuration of the compound 6 is determined by comparing the measured CD spectrum with the ECD spectrum of (2S,7S) calculated by the compound 4, the two have the same Cotton effect between 260-380 bonds, which is caused by n-pi transition of alpha and beta unsaturated ketone bonds, thereby determining that the 7-position configuration of the compound 6 is the same as the 7-position configuration of the compound 4 and is S configuration, and the 2-position configuration of the compound 6 can be further determined as 2S configuration by NOESY spectrum. Thus, the absolute configuration of the compound was determined to be (2S, 7S).
TABLE 6 attribution of NMR data on Compound 6
Figure BDA0001140421780000121
The structural identification data of the compound 7 (2S,3aS) -humulone C are aS follows:
Figure BDA0001140421780000122
a light yellow oil (dichloromethane),
Figure BDA0001140421780000123
9.38(c 3.25 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:401.1950(calcd.401.1935 for C21H30NaO6) It can be seen that the molecular formula is C21H30O6The unsaturation degree was 7.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 7.
The manner of ligation of the individual fragments was determined by HMBC spectroscopy. In HMBC spectra, δH2.84(1H, dd, J ═ 13.5,6.4Hz, H-2"a),2.74(1H, dd, J ═ 13.5,7.5Hz, H-2" b) are remotely related to 199.4(C-1"), so the isobutyl group is attached to the carbonyl; deltaH18.81(6-OH) is associated with 199.4 (C-1'), suggesting that isovaleryl is directly linked to the α -acids mother nucleus; deltaH3.09(1H, dd, J ═ 14.5,6.6Hz, H-1 "'a), 3.03(1H, dd, J ═ 14.5,8.3Hz, H-1"' b) and δC108.7(C-7),120.9(C-2'"),133.0(C-3'"),170.4(C-7a),193.2(C-6) are related remotely, further illustrating that the 6-position isopentenyl group and the 5-position hydroxyl group of the alpha-acid are cyclized to form a five-membered furan ring.
The relative configuration of compound 7 cannot be determined by NOESY spectroscopy, two chiral carbons sharing four relative configurations.
The absolute configuration of the compound is determined by ECD calculation by using a TDDFT (time density functional theory) method, the spectrum measured by an experiment is compared with the ECD spectra of the calculated enantiomers (2S,3aS), (2S,3aR), (2R,3aR) and (2S,3aS), and the ECD spectra are matched with the calculated spectra (2S,3aS), and the ECD spectra show that the ECD spectra have negative Comton effects (Cotton effect) in the regions of 190-. Therefore, the absolute configuration of the compound was determined to be (2S,3 aS).
TABLE 7 NMR data assignment for Compound 7
Figure BDA0001140421780000131
The structural identification data of compound 8 (3S,3' R,5R) -humulone acid B is as follows:
Figure BDA0001140421780000141
colorless needle-shaped crystals (methanol),
Figure BDA0001140421780000142
+29.0(c 2.3 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:323.1097(calcd.323.1101 for C14H20NaO7) It can be seen that the molecular formula is C14H20O7The unsaturation degree is 5.1H-NMR(600MHz,CD3OD) and13C-NMR(150MHz,CD3OD) data are shown in table 8.
The connection mode of each segment is determined by HMBC spectrum which shows deltaH2.96(1H, t-like, J ═ 7.4Hz, H-4') and 24.3 (3' -CH)3),29.5(2"-CH3) 31.6(C-4'),35.5(C-4),58.9(C-3),88.2(C-2'),173.0(C-6),175.0(C-5') relative, suggesting that the A and B loops are directly connected by C-3, 3'; deltaH4.67(1H, dd, J ═ 9.9,6.7Hz, H-5) and 24.8(3' "-CH)3),26.1(2'"-CH3) 35.5(C-4) indicates that the isopropanolate group is attached to C-5.
The relative configuration of Compound 8 was confirmed by NOESY profile in which 4.67(H-5) was associated with 2.65(H-4 a); 2.55(H-4b) and 2.96(H-3'),1.17(3' -CH)3) Correlation; 2.96(H-3') and 1.57 (1' -CH)3) 2.55(H-4b),2.72(H-4' b). Thus, H-5 and H-4a, 2' -CH can be obtained3H-4' b is asA side; h-4b and H-4'a,3' -CH3H-3' is on the same side, and carboxyl hydrogen is active hydrogen, so that four relative configurations are provided.
The absolute configuration of the compound was determined by ECD calculation using TDDFT method. The experimentally determined spectra were compared with the calculated ECD spectra of the enantiomers (3S,3' R,5R), (3R,3' S,5S) and matched with the calculated spectra (3S,3' R,5R), showing a positive Comton effect (Cotton effect) in the region of 190-250 nm. The absolute configuration of compound 8 was thus determined to be 3S,3' R, 5R.
TABLE 8 NMR data assignment for Compound 8
Figure BDA0001140421780000143
Figure BDA0001140421780000151
Structural identification data for racemates of compounds 9 and 10 lupulone H are as follows:
Figure BDA0001140421780000152
colorless needle-shaped crystals (methanol),
Figure BDA0001140421780000153
0(c 0.8 MeOH). HR-ESI-MS gives the peak of the excimer ion [ M + Na ]]+m/z:323.1097(calcd.323.1101 for C14H20NaO7) It can be seen that the molecular formula is C14H20O7The unsaturation degree is 5.1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 9.
The connection mode of each fragment is determined by HMBC spectrum, deltaH2.99(1H, dd, J ═ 15.5,6.8Hz, H-2"a),2.86(1H, dd, J ═ 15.5,6.9Hz, H-2" b) and δC205.9(C-1"),162.9(C-7a), then isobutyl is attached to the carbonyl carbon and isovaleryl is attached to the carbon at the 7 position; deltaH7.19(1H, d, J ═ 8.2Hz, H-4) with 29.5(C-3), δH3.15(1H, dd, J ═ 15.3,9.1Hz, H-3a),3.07(1H, dd, J ═ 15.1,9.6Hz, H-3b) are associated with 71.7(C-1'),91.6(C-2),117.6(C-3a), suggesting that the five-membered furan epoxy atom is attached to position 7 a.
The NOESY spectrum of the compound shows that 7.19(H-4) is related to 3.15(H-3a),3.07(H-3b), thus further illustrating that the five-membered furan epoxy atom is attached to the 7a position rather than the 3a position.
Due to racemates of compounds 9 and 10
Figure BDA0001140421780000154
0(c 0.8MeOH), the compound was racemic and we resolved compound 9 and 10 racemates using a chiral chromatography column (CHIRALPAK IF, Daicel Chemical Industries, ltd., Japan) (mobile phase n-hexane: ethanol 95:5, flow rate 1mL/min, detection wavelength 210 nm). The retention times of the two isomers were R-lupulone H (9) (10.565min) and S-lupulone H (10) (12.826min), with a peak area ratio of 1: 1. The absolute configuration of the compound is determined by ECD calculation by using a TDDFT (time density functional theory) method, and a spectrogram measured by an experiment is compared with ECD spectrograms of enantiomers 2R and 2S obtained by calculation, so that a CD spectrogram of 9 is determined to be matched with a calculated spectrogram (2R), and a CD spectrogram of 10 is determined to be matched with the calculated spectrogram (2S). Therefore, the absolute configuration of the two compounds 9 obtained by chiral resolution is determined to be (2R), and the absolute configuration of 10 is determined to be (2S).
TABLE 9 NMR data assignment for racemates of Compounds 9 and 10
Figure BDA0001140421780000155
Figure BDA0001140421780000161
Structural identification data for racemates of Compounds 11 and 12 lupulone G are as follows:
Figure BDA0001140421780000162
colorless needle-shaped crystals (methanol),
Figure BDA0001140421780000163
0(c 0.25MeOH)。1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 10.
The connection mode of each fragment is determined by HMBC spectrum, deltaH3.75(1H, m) and δC209.9(C-1"),160.4(C-7a), then the isopropyl group is attached to the carbonyl carbon and the isobutyryl group is attached to the carbon at the 7 position; deltaH7.28(1H, d, J ═ 8.2Hz, H-4) correlates with 28.4(C-3), δH3.14-2.99(2H, m) is associated with 69.9(C-1'),91.3(C-2),118.5(C-3a), suggesting that the five-membered furan epoxy atom is attached to position 7 a.
The NOESY spectrum of the compound shows that 7.28(H-4) is associated with 3.14-2.99(H-3), thus further illustrating that the five-membered furan epoxy atom is attached to the 7a position rather than the 3a position.
Due to the racemate of compounds 11 and 12
Figure BDA0001140421780000164
0(c 0.25MeOH), the compound was racemic and we resolved the racemates of compounds 11 and 12 using a chiral column (CHIRALPAK IF, Daicel Chemical Industries, ltd., Japan) (mobile phase n-hexane: ethanol 95:5, flow rate 1mL/min, detection wavelength 210 nm). The retention times of the two isomers were R-lupulone G (11) (9.958min) and S-lupulone G (12) (11.304min), with a peak area ratio of 1: 1. The absolute configuration of the compound is determined by ECD calculation by using a TDDFT method, and a spectrogram measured in an experiment is compared with ECD spectrograms of enantiomers 2R and 2S obtained by calculation, so that a CD spectrogram of 11 is determined to be matched with a calculated spectrogram (2R), and a CD spectrogram of 12 is determined to be matched with the calculated spectrogram (2S). Therefore, the absolute configuration of the two compounds 11 obtained by chiral resolution is determined to be (2R), and the absolute configuration of 12 is determined to be (2S).
TABLE 10 assignment of NMR data on racemates of Compounds 11 and 12
Figure BDA0001140421780000165
Figure BDA0001140421780000171
The structural identification data for compound 13 and 14 racemates 5-deprenyllupulonol C are as follows:
Figure BDA0001140421780000172
colorless needle-shaped crystals (methanol),
Figure BDA0001140421780000173
0(c 0.16MeOH)。1H-NMR(400MHz,CDCl3) And13C-NMR(100MHz,CDCl3) The data are shown in Table 11.
The connection mode of each fragment is determined by HMBC spectrum, deltaH2.88(1H, dd, J ═ 15.0,6.6Hz, H-2"a),2.79(1H, dd, J ═ 15.0,7.3Hz, H-2" b) and δC203.5(C-1"),160.7(C-7a), then isobutyl is attached to the carbonyl carbon and isovaleryl is attached to the carbon at the 7-position; deltaH2.98(2H, d, J ═ 9.1Hz, H-3) associated with 69.9(C-1'),90.7(C-2),106.9(C-3a), suggesting that the five-membered furan epoxy atom is attached at position 7 a. DeltaH3.12(2H, d, J ═ 7.2Hz, H-1 "') associated with 106.9(C-3a),104.0(C-5),123.3 (C-2"'), suggesting that the isopentenyl group is attached to C-4, further indicating that the five-membered furan epoxy atom is attached to position 7a but not 3 a.
Due to racemate of compounds 13 and 14
Figure BDA0001140421780000174
0(c 0.16MeOH), the compound was racemic and we resolved the racemates of compounds 13 and 14 using a chiral column (CHIRALPAK IF, Daicel Chemical Industries, ltd., Japan) (mobile phase n-hexane: ethanol 95:5, flow rate 1mL/min, detection wavelength 210 nm). The retention times of the two isomers were (R) -5-deprenyllupulol C (13) (7.220min) and(S) -5-deprenyllupulonol C (14) (9.597min) with a peak area ratio of 1: 1. The absolute configuration of the compound is determined by ECD calculation by using a TDDFT method, and a spectrogram measured in an experiment is compared with ECD spectrograms of enantiomers 2R and 2S obtained by calculation, so that a CD spectrogram of 13 is determined to be matched with a calculated spectrogram (2R), and a CD spectrogram of 14 is determined to be matched with the calculated spectrogram (2S). Therefore, the absolute configuration of the two compounds 13 obtained by chiral resolution is determined to be (2R), and the absolute configuration of 14 is determined to be (2S).
TABLE 11 assignment of NMR data on racemates of Compounds 13 and 14
Figure BDA0001140421780000181
Example 2
(1) Reflux-extracting 1000g of flos Lupuli with 95% ethanol under heating for 3 times (dosage: 10L), and recovering extractive solution under reduced pressure to obtain crude extract;
(2) separating the ethanol extract obtained in the step (1) by silica gel column chromatography, and sequentially adding petroleum ether: acetone 100:1, 100:3,100:6,100:9, 100:11,100:15, 5:1,1:1 elution,
(3) the petroleum ether obtained in the step (2): separating acetone 100:3 by ODS chromatography, and gradient eluting with acetonitrile/water 1:9,2:8,4:6,1:1,6:4 as mobile phase;
(4) acetonitrile obtained in the step (3): the water (4:6) fraction was separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (3:7) as mobile phase to obtain new alpha-acid, compound 9 and 10 racemate (t)R60min, yield 0.011%) and compound 4 (t)R75min) (yield 0.043%). Compound 9 and 10 racemates (t)R60min, yield 0.011%) and compound 4 (t)R75min) (yield 0.043%). The racemates of compounds 9 and 10 were separated by chiral column chromatography using n-hexane: elution with ethanol (90:10) as the mobile phase yielded new alpha-acids 9(13.642min),10(15.796min) (0.005% yield each).
(5) Acetonitrile obtained in the step (3): water (2:8) fraction through the crystallization solvent acetonitrile: water (4:6) was repeatedly recrystallized to obtain racemates of compounds 13 and 14 (yield 0.040%). The racemates of compounds 13 and 14 are separated by chiral column chromatography using n-hexane: eluting with ethanol (90:10) as mobile phase to obtain new alpha-acids 13(10.574min),14(14.078min) (yield 0.019% each).
(6) The petroleum ether obtained in the step (2): separating acetone 100:6 by ODS chromatography, and gradient eluting with acetonitrile/water 1:9, 3:7, 4:6,1:1,6:4 as mobile phase;
(7) acetonitrile obtained in the step (6): the water (3:7) fractions were separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (4:6) as mobile phase to obtain new alpha-acid, compound 1 (t)R48min) (yield 0.076%) and compound 5 (t)R60min) (yield 0.093%).
(8) The petroleum ether obtained in the step (2): performing ODS chromatographic separation on a 100:9 acetone flow, and performing gradient elution by using acetonitrile/water at a ratio of 1:9,2:8,4:6,1:1 and 6:4 as mobile phases;
(9) acetonitrile obtained in the step (8): the water (2:8) fraction was separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (38: 62) as mobile phase to obtain new alpha-acid, compound 7 (t)R75min) (yield 0.025%).
(10) The petroleum ether obtained in the step (2): performing ODS chromatographic separation on a 100:11 acetone flow, and performing gradient elution by using acetonitrile/water 1:9, 3:7,1:1 and 6:4 as mobile phases;
(11) acetonitrile obtained in the step (10): the water (3:7) fractions were separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (35: 65) as mobile phase to obtain new alpha-acid, compound 2 (t)R50min, yield 0.014%), compound 3 (t)R64min, yield 0.041%), compound 6 (t)R40min, yield 0.015%), compound 11 and 12 racemate (t)R70min, yield 0.009%). The racemates of compounds 11 and 12 were separated by chiral column chromatography using n-hexane: elution with ethanol (90:10) as the mobile phase yielded new α -acids 11(13.124min),12(14.964min) (0.004% each yield).
(12) The petroleum ether obtained in the step (2): separating the acetone 5:1 by ODS chromatography, and performing gradient elution with acetonitrile/water 1:9, 3:7,1:1, 6:4 as mobile phases;
(13) acetonitrile obtained in the above step (12): water (3:7) fraction through the crystallization solvent acetonitrile: repeated recrystallization of water (2:8) gave the new α -acid, compound 8 (yield 0.043%).
The structure of alpha-acids 1-14 was identified as in example 1.
Example 3
(1) Extracting flos Lupuli 2000g with 100% ethanol for 2 times (dosage: 16L), and recovering extractive solution under reduced pressure to obtain crude extract;
(2) separating the ethanol extract obtained in the step (1) by silica gel column chromatography, sequentially adding chloroform: acetone 100:1, 100:2, 100:4, 100:6,100: 8, 100:9, 100:11,100:15, 5: 1;
(3) chloroform obtained in the above step (2): performing ODS chromatographic separation on 100:2 fractions of acetone, and performing gradient elution by using acetonitrile/water at a ratio of 1:9,2:8,4:6,1:1 and 6:4 as mobile phases;
(4) acetonitrile obtained in the step (3): the water (4:6) fraction was separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (38: 62) as mobile phase to obtain new alpha-acid, compound 9 and 10 racemate (t)R42min, yield 0.010%) and compound 4 (t)R55min) (yield 0.044%). The racemates of compounds 9 and 10 were separated by chiral column chromatography using n-hexane: elution with ethanol (93:7) as the mobile phase yielded new alpha-acids 9(11.725min),10(13.956min) (0.005% yield each).
(5) Acetonitrile obtained in the step (3): water (4:6) fraction through the crystallization solvent acetonitrile: water (3:7) and repeated recrystallization techniques gave racemates of compounds 13 and 14 (yield 0.044%). The racemates of compounds 13 and 14 are separated by chiral column chromatography using n-hexane: elution with ethanol (93:7) as the mobile phase yielded new alpha-acids 13(7.972min),14(10.491min) (0.022% yield each).
(6) Chloroform obtained in the above step (2): separating acetone 100:4 by ODS chromatography, and gradient eluting with acetonitrile/water 1:9, 3:7,1:1, 6:4 as mobile phase;
(7) acetonitrile obtained in the step (6): the water (3:7) fractions were separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (1:1) as mobile phase to obtain new alpha-acid, compound 1 (t)R35min) (yield 0.074%) and compound 5 (t)R44min) (yield 0.093%).
(8) Chloroform obtained in the above step (2): performing ODS chromatographic separation on a 100:6 acetone flow, and performing gradient elution by using acetonitrile/water 1:9, 4:6,1:1 and 6:4 as mobile phases;
(9) acetonitrile obtained in the step (8): the water (4:6) fraction was separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (1:1) as mobile phase to obtain new alpha-acid, compound 7 (t)R50min) (yield 0.026%).
(10) Chloroform obtained in the above step (2): performing ODS chromatographic separation on a 100:9 acetone flow, and performing gradient elution by using acetonitrile/water 2:8, 3:7,1:1 and 6:4 as mobile phases;
(11) acetonitrile obtained in the step (10): the water (3:7) fractions were separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (35: 65) as mobile phase to obtain new alpha-acid, compound 2 (t)RYield 0.012% over 40min, compound 3 (t)R52min, yield 0.035%), compound 6 (t)R30min, yield 0.014%), compound 11 and 12 racemate (t)R60min, yield 0.012%). The racemates of compounds 11 and 12 were separated by chiral column chromatography using n-hexane: elution with ethanol (93:7) as the mobile phase yielded new α -acids 11(11.043min),12(12.412min) (0.006% yield each).
(12) Chloroform obtained in the above step (2): performing ODS chromatographic separation on a 100:15 acetone flow, and performing gradient elution by using acetonitrile/water at a ratio of 1:9,2:8,4:6,1:1 and 6:4 as mobile phases;
(13) acetonitrile obtained in the above step (12): water (1: 9) fraction through the crystallization solvent acetonitrile: water (2:8), repeated recrystallization to give neo- α -acid, compound 8 (yield 0.040%).
The structure of alpha-acids 1-14 was identified as in example 1.
Example 4
(1) Extracting flos Lupuli 1500g with 80% ethanol for 1 time (dosage: 22.5L), and recovering extractive solution under reduced pressure to obtain crude extract;
(2) separating the ethanol extract obtained in the step (1) by silica gel column chromatography, sequentially adding chloroform: methanol 100:1, 100:2.5, 100:4, 100:6,100: 8, 100:10, 100:12, 100:15, 5: 1;
(3) chloroform obtained in the above step (2): the methanol 100:1 stream was fractionated by ODS chromatography using methanol/water 3:7,1:1,7:3 and 9:1 are mobile phase gradient elution;
(4) the methanol obtained in the step (3): the water (1:1) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (6: 4) as mobile phase to obtain new alpha-acid, compound 9 and 10 racemate (t)R59min, yield 0.011%) and compound 4 (t)R74min) (yield 0.048%). The racemates of compounds 9 and 10 were separated by chiral column chromatography using n-hexane: elution with ethanol (92:8) as the mobile phase yielded new alpha-acids 9(12.739min),10(14.750min) (0.005% yield each).
(5) The methanol obtained in the step (3): water (1:1) fraction through the crystallization solvent methanol: repeated recrystallization techniques with water (8:2) gave the racemates of compounds 13 and 14 (yield 0.041%). The racemates of compounds 13 and 14 are separated by chiral column chromatography using n-hexane: elution with ethanol (92:8) as the mobile phase yielded the new alpha-acids 13(9.327min),14(11.576min) (0.020% yield each).
(6) Chloroform obtained in the above step (2): the methanol 100:4 stream was fractionated by ODS chromatography using a methanol/water 4:6,1:1,6:4 is mobile phase gradient elution;
(7) the methanol obtained in the step (6): the water (4:6) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (56: 44) as mobile phase to obtain new alpha-acids 1 (t)R62min) (yield 0.072%) and 5 (t)R75min) (yield 0.093%).
(8) Chloroform obtained in the above step (2): the methanol 100:6 stream was fractionated by ODS chromatography using methanol/water 4:6,1:1,6:4 is mobile phase gradient elution;
(9) the methanol obtained in the step (8): the water (4:6) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (66: 34) as mobile phase to obtain new alpha-acids 7 (t)R90min) (yield 0.023%).
(10) Chloroform obtained in the above step (2): separating methanol 100:6 by ODS chromatography, and gradient eluting with methanol/water 2:8,4:6,1:1,6:4, 9:1 as mobile phase;
(11) the methanol obtained in the step (10): the water (1:1) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (1:1) as mobile phase to obtainNovel alpha-acids 2 (t)R69min, yield 0.013%), 3 (t)R80min, yield 0.040%), 6 (t)R57min, yield 0.015%), compound 11 and 12 racemate (t)R65min, yield 0.010%). The racemates of compounds 11 and 12 were separated by chiral column chromatography using n-hexane: elution with ethanol (92:8) as the mobile phase yielded new alpha-acids 11(11.872min),12(13.519min) (0.005% yield each).
(12) Chloroform obtained in the above step (2): the methanol 10:1 stream was fractionated by ODS chromatography using methanol/water 4:6,1:1,6:4 is mobile phase gradient elution;
(13) the methanol obtained in the step (12): water (4:6) fraction through the crystallization solvent methanol: water (6: 4) was repeatedly recrystallized to give new alpha-acids 8 (yield 0.041%).
The structure of the alpha-acid derivatives 1-14 was identified as described in example 1.
Example 5
(1) Extracting flos Lupuli 2000g with 75% ethanol for 1 time (dosage: 10L), and recovering extractive solution under reduced pressure to obtain crude extract;
(2) separating the ethanol extract obtained in the step (1) by silica gel column chromatography, and sequentially adding dichloromethane: acetone 100:1, 100:2, 100:3,100: 4, 100:6,100: 8, 100:9, 100:11,100:15, 5: 1;
(3) dichloromethane obtained in the above step (2): performing ODS chromatographic separation on 100:2 fractions of acetone, and performing gradient elution by using methanol/water 3:7,1:1 and 7: 3as mobile phases;
(4) the methanol obtained in the step (3): the water (1:1) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (67: 33) as mobile phase to obtain new alpha-acid, compound 9 and 10 racemate (t)R50min, yield 0.011%) and compound 4 (t)R68min) (yield 0.045%). The racemates of compounds 9 and 10 were separated by chiral column chromatography using n-hexane: elution with ethanol (94:6) as the mobile phase yielded new alpha-acids 9(10.965min),10(13.226min) (0.005% yield each).
(5) The methanol obtained in the step (3): water (7:3) fraction through the crystallization solvent methanol: repeated recrystallization from water (9:1) gave the racemates of compounds 13 and 14 (yield 0.041%). The racemates of compounds 13 and 14 are separated by chiral column chromatography using n-hexane: eluting with ethanol (94:6) as mobile phase to obtain new alpha-acids 13(7.720min),14(9.997min) (yield 0.019% each).
(6) Dichloromethane obtained in the above step (2): separating acetone 100:3 by ODS chromatography, and gradient eluting with methanol/water 4:6,1:1,6:4 as mobile phase;
(7) the methanol obtained in the step (6): the water (4:6) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (6: 4) as mobile phase to obtain new alpha-acid, compound 1 (t)R61min) (yield 0.073%) and compound 5 (t)R78min) (yield 0.093%).
(8) Dichloromethane obtained in the above step (2): separating acetone 100:4 by ODS chromatography, and gradient eluting with methanol/water 2:8,4:6,1:1,6:4 as mobile phase;
(9) the methanol obtained in the step (8): the water (1:1) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (77: 23) as mobile phase to obtain new alpha-acid, compound 7 (t)R69min) (yield 0.025%).
(10) Dichloromethane obtained in the above step (2): separating the acetone 100:8 by ODS chromatography, and performing gradient elution with methanol/water 3:7,1:1,7: 3as mobile phase;
(11) the methanol obtained in the step (10): the water (7:3) fraction was separated by HPLC-RID chromatography, eluting with methanol: eluting with water (6: 4) as mobile phase to obtain new alpha-acid, compound 2 (t)R65min, yield 0.013%), compound 3 (t)R76min, yield 0.035%), compound 6 (t)R48min, yield 0.014%), compound 11 and 12 racemate (t)R80min, yield 0.009%). The racemates of compounds 11 and 12 were separated by chiral column chromatography using n-hexane: elution with ethanol (94:6) as the mobile phase yielded new α -acids 11(10.558min),12(11.804min) (0.004% each yield).
(12) Dichloro obtained in the step (2): performing ODS chromatographic separation on a 100:15 acetone flow, and performing gradient elution by using methanol/water 2:8,4:6,1:1,6:4 and 9:1 as mobile phases;
(13) the methanol obtained in the step (12): water (1:1) fraction through the crystallization solvent methanol: repeated recrystallization techniques with water (6: 4) yielded new alpha-acids, compound 8 (yield 0.042%).
The structure of alpha-acids 1-14 was identified as in example 1.
Example 6
(1) Extracting flos Lupuli 1500g with 95% ethanol for 1 time (dosage: 30L), and recovering extractive solution under reduced pressure to obtain crude extract;
(2) separating the ethanol extract obtained in the step (1) by silica gel column chromatography, and sequentially adding dichloromethane: methanol 100:1, 100:3,100: 5, 100:6,100:9, 100:12, 100:15, 5: 1;
(3) dichloromethane obtained in the above step (2): the methanol 100:1 stream was separated by ODS chromatography using acetonitrile/water 1:9, 3:7,1:1,7:3, and performing gradient elution by using a mobile phase;
(4) acetonitrile obtained in the step (3): the water (3:7) fractions were separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (1:1) as mobile phase to obtain new alpha-acid, compound 9 and 10 racemate (t)R40min, yield 0.013%) and compound 4 (t)R55min) (yield 0.047%). The racemates of compounds 9 and 10 were separated by chiral column chromatography using n-hexane: elution with ethanol (93:7) as the mobile phase yielded new alpha-acids 9(11.865min),10(13.933min) (0.006% yield each).
(5) Acetonitrile obtained in the step (3): water (1:1) fraction through the crystallization solvent acetonitrile: water (4:6) was repeatedly subjected to recrystallization to obtain racemates of compounds 13 and 14 (yield 0.039%). The racemates of compounds 13 and 14 are separated by chiral column chromatography using n-hexane: elution with ethanol (93:7) as the mobile phase yielded the new α -acids 13(8.150min),14(10.608min) (0.018% yield each).
(6) Dichloromethane obtained in the above step (2): separating methanol 100:3 by ODS chromatography, and performing gradient elution with acetonitrile/water 1:9,2:8,4:6,1:1,6:4 as mobile phase;
(7) acetonitrile obtained in the step (6): the water (2:8) fraction was separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (33: 67) as mobile phase to obtain new alpha-acid 1 (t)R54min) (yield 0.073%) and 5 (t)R62min) (yield 0.095%).
(8) Dichloromethane obtained in the above step (2): separating methanol 100:5 by ODS chromatography, and performing gradient elution with acetonitrile/water 1:9,2:8, 1:1,7: 3as mobile phases;
(9) acetonitrile obtained in the step (8): the water (2:8) fraction was separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (38: 62) as mobile phase to obtain new alpha-acids 7 (t)R68min) (yield 0.025%).
(10) Dichloromethane obtained in the above step (2): the methanol 100:6 stream was ODS chromatographed using acetonitrile/water 1:9, 3:7,1:1, 6:4, and performing gradient elution by using a mobile phase;
(11) acetonitrile obtained in the step (10): the water (3:7) fractions were separated by HPLC-RID chromatography, eluting with acetonitrile: eluting with water (4:6) as mobile phase to obtain new alpha-acid 2 (t)RYield 0.013% 3 (t) 42minR54min, yield 0.041%), 6 (t)RYield 0.016% for 30min, compound 11 and 12 racemate (t)R65min, yield 0.013%). The racemates of compounds 11 and 12 were separated by chiral column chromatography using n-hexane: elution with ethanol (93:7) as the mobile phase yielded new α -acids 11(11.045min),12(12.610min) (0.006% yield each).
(12) Dichloromethane obtained in the above step (2): the methanol 10:1 stream was ODS chromatographed using acetonitrile/water 1:9,2:8,4:6,1:1,6:4 is mobile phase gradient elution;
(13) acetonitrile obtained in the above step (12): water (2:8) fraction through the crystallization solvent acetonitrile: repeated recrystallization of water (3:7) gave the new alpha-acids 8 (yield 0.043%).
The structure of the alpha-acid derivatives 1-14 was identified as described in example 1.
EXAMPLE 7 anti-neuritic Activity test of novel alpha-acid derivatives 1-14 prepared in examples 1-6
(1) The experimental principle is as follows: the chronic inflammatory reaction mediated by the microglia activation is an important link in the generation and development process of neurodegenerative diseases, and the inhibition of the microglia activation can become a new target point for drug discovery. LPS activates microglia to release NO, proinflammatory cytokines, active oxygen and the like. The anti-inflammatory activity of the new alpha-acid derivatives 1-14 is evaluated by establishing a screening model for abnormal activation of BV2 microglia activated by in vitro LPS and taking NO released by activated microglia as an index.
(2) The experimental method comprises the following steps:
culture of mouse microglia line BV2
All glassware and metal instruments (culture bottles, pipettes, solution bottles, etc.) used in cell culture and model building were autoclaved at 121 ℃ for 30min to completely remove the contaminated LPS. A cell culture solution containing 10% fetal calf serum and 50. mu.M 2-mercaptoethanol was prepared on the basis of DMEM medium. Microglia at about 4 × 105cells/ml at 5% CO2And subculturing in a culture bottle at 37 ℃, wherein the adherent cells account for 50-60% of the bottom area of the culture bottle by the third day, digesting the adherent cells by pancreatin, and subculturing to another culture bottle. BV2 thawed in a refrigerator at the ultralow temperature of-80 ℃ is taken as the first generation, and BV2 cells of 3 th to 8 th generations are selected for experiments.
② process for preparing medicine
Test compounds were all in powder form, dissolved in DMSO. A mother liquor was prepared at a concentration of 50mM and stored at-20 ℃. It was diluted with DMEM medium at the time of use to 100. mu.M, 30. mu.M, 10. mu.M, 3. mu.M, and 1. mu.M in this order. The final concentration of DMSO is less than 1 ‰.
③ Griess method for detecting inhibition of compound to LPS activated microglia
Taking BV2 microglia in logarithmic growth phase, adjusting the cell density to 3X 10 by using fresh DMEM medium containing 5% fetal calf serum5cells/ml, seeded in 96-well plates, 100. mu.l/well, 5% CO at 37 ℃2Culturing in the incubator. And replacing the cells with serum-free fresh culture solution after 24 hours of adherent culture, and simultaneously adding drugs. Each compound was co-administered with LPS at 1, 3,10, 30, 100. mu.M. Blank control was also set. The final concentration of LPS in each administration group was 100 ng/ml. Continuously culturing for 24h after adding medicine into cells, collecting supernatant, and detecting NO in the supernatant by Griess colorimetric method2-And (4) content.
MTT method for detecting influence of compound on survival rate of microglia cell
Taking logarithmic growth phase for cultureBV2 microglia, cell density adjusted to 3X 10 with fresh DMEM medium containing 5% fetal bovine serum5cells/ml, seeded in 96-well plates, 100. mu.l/well, 5% CO at 37 ℃2Culturing in the incubator. After the cells are cultured for 24 hours adherent, the cells are changed into fresh culture solution, and meanwhile, the cells are treated by adding medicine. Each compound was co-administered with LPS at 1, 3,10, 30, 100. mu.M. Blank control was also set. The final concentration of LPS in each administration group was 100 ng/ml. The cells were incubated for 24h after addition of the drug, then MTT solution, 10. mu.l/well, was added to the cell broth, the cells were incubated with 0.25mg/ml MTT at 37 ℃ for 3h, the culture broth was aspirated, then 100. mu.l of DMSO solution was added, and the OD of the optical density was determined. And (3) processing data, namely processing the data by using corresponding software of a microplate reader, calculating an average value of OD values of 6 holes of each sample, and calculating the cell survival rate (CV%) by using the average value according to the following formula.
Percent cell survival%
Fifthly, statistical method
All data were examined using the SPSS (13.0) statistical software package. Results are expressed as mean ± standard error, and the global differences were evaluated, and the means between groups was analyzed by One-Way ANOVA analysis for homogeneity of variance and by Dunnett's test analysis for comparison between groups. The multiple sample homogeneity of variance test was conducted using a Leven test, where the variances were uniform when p >0.05, the differences in mean among the groups were tested using Dunnett's two-sided T, and the differences in mean among the groups were tested using Dunnett T3 when p <0.05 and the variances were not uniform.
⑥IC50Is calculated by
Calculating IC by nonlinear regression fitting of parameters such as each dosage and inhibition rate50
(3) The experimental results are as follows: see Table 12
TABLE 12 results of experiments on the inhibitory effect of novel alpha-acid derivatives 1 to 14 on microglial activation
Figure BDA0001140421780000241
Significance:*P<0.05,**P<0.01,***P<0.001 compared to LPS-induced group;###P<0.001 compared to the control group.
As a result, it was found that the novel α -acids prepared in examples 1 to 6 were 1,9, 10,11,12,13,14 (30 μ M, 100 μ M); 3, 5, 7(100 μ M) can remarkably inhibit LPS-induced release of excessive activated BV2 microglia NO; compounds 2, 4, 6, 8 showed potential NO release inhibiting activity with increasing concentration.
Example 13 Effect of the novel alpha-acid derivatives 1-14 prepared in examples 1-6 on protecting Hydrogen peroxide-induced liver cell injury of HepG2
(1) The experimental principle is as follows: the establishment of an in vitro hepatocyte damage model is necessary for the screening of the liver protection effect of the drug and the research of the molecular action mechanism. Wherein the oxidative damage model of liver cells comprises CCl4And H2O2Due to CCl4The induction model has more lasting effect, higher cytotoxicity, poor controllability of actual operation, unstable injury effect, uneven injury, and H2O2The induction model has more direct effect and is mainly used for short-time acute injury, so H is selected in the experiment2O2As a model for injury. H2O2Is a strong oxidant, is a classical agent for inducing oxidative damage of cells, is also a common active oxygen in vivo, and plays a key role in various tissue injuries. H2O2After the liver cell is acted, the liver cell can be metabolized and decomposed by cytochrome P-450 to generate OH free radicals, unsaturated fatty acid in cell biological membranes is attacked, lipid peroxidation is initiated, endogenous GSH is greatly consumed, accumulation of peroxide MDA is increased, and cell death is finally caused. At present, two types of cells, L-02 (normal human liver cells) and HepG2, are commonly used for establishing in vitro models of liver cell injury. In this experiment, the HepG2 cell system was used to evaluate the effect of 14 new derivatives on protecting liver cells.
(2) Experimental methods
Preparation of main reagent
Preparing a vitamin E stock solution: precisely 20mg, and 232.2. mu.l of DMSO was added to prepare a 200mM stock solution, which was stored at-20 ℃ for further use.
Preparing hydrogen peroxide stock solution: precisely extract 3.3. mu.l of 30% H2O2Then, DMEM was added to the solution to a volume of 10. mu.l to prepare a 3200. mu.M stock solution, and the stock solution was stored at-20 ℃ for further use.
Experiment grouping: normal control group, H2O2Model group, vitamin E + H2O2Compound (1,10, 50. mu.M) + H2O2The total number of the groups is 6, and each group is provided with 3 multiple holes.
Step three, experiment:
taking HepG2 cells in logarithmic growth phase at 6X 104The cells/ml were inoculated in 96-well plates at 37 ℃ in 5% CO2Culturing for 24h in an incubator; cells were pretreated with vitamin E (500. mu.M) and compound (1,10, 50. mu.M) for 6 h; addition of H2O2Culturing for 2h (200 μ M); cell viability was measured by the MTT method at 490nm wavelength.
Survival (%) < 100% (experiment OD-blank OD)/(control OD-blank OD) ×
The protection rate (%) was (sample group OD-lesion OD)/(normal group OD-lesion OD) × 100%
Fourthly, statistical method
Using SPSS17.0 statistical software, each group of data was represented by Mean + -SE, analysis was performed using one-way variance (ANOVA), and comparisons between pairs of means between groups were performed using LSD, with P <0.05 being a difference of statistical significance.
(4) Results of the experiment
As shown in fig. 1 and 2
The results show that the novel alpha- acid derivatives 2, 8, 9,10,11,12,13,14 prepared in examples 1 to 6 can significantly protect H2O2Induced oxidative damage to HepG2 hepatocytes; compound 7 has moderate-strength hepatocyte protective activity; compounds 1, 3, 4, 5,6 exhibited some degree of hepatoprotective activity at the tested concentrations.
Example 14 Effect of the novel alpha-acid derivatives 1 to 14 prepared in examples 1 to 6 on protection of Hydrogen peroxide-induced liver cell injury of L02
(1) The experimental principle is as follows: as described above. In this experiment the L02 cell system was used to evaluate the effect of 14 new compounds on protecting liver cells.
(2) Experimental methods
Preparation of main reagent
Preparing a vitamin E stock solution: precisely 20mg, and 232.2. mu.l of DMSO was added to prepare a 200mM stock solution, which was stored at-20 ℃ for further use.
Preparing hydrogen peroxide stock solution: precisely extract 3.3. mu.l of 30% H2O2Then, DMEM was added to the solution to a volume of 10. mu.l to prepare a 3200. mu.M stock solution, and the stock solution was stored at-20 ℃ for further use.
Experiment grouping: normal control group, H2O2Model group, vitamin E + H2O2Compound (1,10, 50. mu.M) + H2O2The total number of the groups is 6, and each group is provided with 3 multiple holes.
Step three, experiment:
taking L-02 cells in logarithmic growth phase at 8X 104The cells were inoculated into 96-well culture plates at a density of one cell/ml, and incubated at 37 ℃ in 5% CO2Culturing for 24h in an incubator; cells were pretreated with vitamin E (500. mu.M) and compound (1,10, 50. mu.M) for 6 h; addition of H2O2Culturing for 2h (100 μ M); cell viability was measured by the MTT method at 490nm wavelength.
Survival (%) < 100% (experiment OD-blank OD)/(control OD-blank OD) ×
The protection rate (%) was (sample group OD-lesion OD)/(normal group OD-lesion OD) × 100%
Fourthly, statistical method
Using SPSS17.0 statistical software, each group of data was represented by Mean + -SE, analysis was performed using one-way variance (ANOVA), and comparisons between pairs of means between groups were performed using LSD, with P <0.05 being a difference of statistical significance.
(5) Results of the experiment
As shown in fig. 3, 4
The results show that the novel alpha- acids 2, 8, 9,10,11,12,13,14 prepared in examples 1 to 6 can significantly protectH protector2O2Induced oxidative damage to L-02 hepatocytes; compound 7 has moderate-strength hepatocyte protective activity; compounds 3, 4, 5,6 exhibited some degree of hepatoprotective activity at the tested concentrations.

Claims (8)

1. The following is a description of the present inventionα-an acid derivative, characterized by having the following structure:
Figure DEST_PATH_IMAGE002
Figure DEST_PATH_IMAGE004
Figure DEST_PATH_IMAGE006
Figure DEST_PATH_IMAGE008
Figure DEST_PATH_IMAGE010
Figure DEST_PATH_IMAGE012
。
2. according to claim 1α-a process for the preparation of acid derivatives, characterized in that: the method comprises the following steps:
(1) hop (Humulus lupulusL.) extracting with 50-100% ethanol, and recovering the extract to obtain a crude extract;
(2) separating the crude extract obtained in the step (1) by silica gel column chromatography, and performing gradient elution by using one mixed solvent of petroleum ether and ethyl acetate mixed solvent, petroleum ether and acetone mixed solvent, chloroform and acetone mixed solvent, dichloromethane and acetone mixed solvent, chloroform and methanol mixed solvent or dichloromethane and methanol mixed solvent;
(3) performing ODS column chromatographic separation on the fraction (100: 1-100: 25) obtained in the step (2), and performing gradient elution by using a mixed solvent of methanol and water or a mixed solvent of acetonitrile and water as a mobile phase;
(4) fraction 1 obtained in the above step (3): performing further separation by HPLC-RID10A at ratio of 9-7: 3, and performing gradient elution by using a mixed solvent of methanol and water or using a mixed solvent of acetonitrile and water as a mobile phase to obtainαAcid derivatives 1 to 6.
3. According to claim 2α-a process for the preparation of acid derivatives, characterized in that: the flos Lupuli is Humulus (Humulus) of Moraceae (Moraceae)Humulus) Plant Humulus lupulus (Humulus lupulus L.) (Humulus lupulusL.) dried female inflorescences.
4. According to claim 2α-a process for the preparation of acid derivatives, characterized in that: the extraction method in the step (1) is heating reflux extraction or heating ultrasonic extraction for 1-3 times, the used solvent is 50-100% of ethanol, and the medicinal materials are as follows: the weight-volume ratio of the solvent is 1: 5-1: 25.
5. According to claim 2α-a process for the preparation of acid derivatives, characterized in that: the volume ratio of the mixed solvent of the eluting solvent petroleum ether and the ethyl acetate and the mixed solvent of the petroleum ether and the acetone in the step (2) is 100: 1-1: 1, the volume ratio of a mixed solvent of dichloromethane and acetone, a mixed solvent of chloroform and acetone, a mixed solvent of dichloromethane and methanol, or a mixed solvent of chloroform and methanol is 100: 1-100: 20.
6. according to claim 2α-a process for the preparation of acid derivatives, characterized in that: in the step (3), the volume ratio of the methanol-water mixed solvent is 2: 8-9: 1, and the volume ratio of the acetonitrile-water mixed solvent is 1: 9-7: 3.
7. according to the rightThe method according to claim 2α-a process for the preparation of acid derivatives, characterized in that: the volume ratio of the mobile phase methanol and water mixed solvent in the step (4) is 1: 1-8: 2, the volume ratio of the acetonitrile-water mixed solvent is 2: 8-1: 1.
8. the method of claim 1αApplication of acid derivatives in preparing medicines for preventing and treating liver injury and neurodegenerative diseases.
CN201610944141.8A 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof Active CN108017604B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610944141.8A CN108017604B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof
CN202110396943.0A CN113149944B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610944141.8A CN108017604B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110396943.0A Division CN113149944B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN108017604A CN108017604A (en) 2018-05-11
CN108017604B true CN108017604B (en) 2021-05-07

Family

ID=62069900

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110396943.0A Active CN113149944B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof
CN201610944141.8A Active CN108017604B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110396943.0A Active CN113149944B (en) 2016-11-02 2016-11-02 Alpha-acid derivative and preparation method and application thereof

Country Status (1)

Country Link
CN (2) CN113149944B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139479A1 (en) * 2001-08-10 2003-02-27 Schwabe Willmar Gmbh & Co Hop extracts, process for their preparation and use
CN103232420A (en) * 2013-04-17 2013-08-07 沈阳药科大学 Zedoary turmeric lactone enantiomer and preparation method thereof
CN104586945B (en) * 2014-12-05 2018-06-19 沈阳药科大学 Hops extractive of general flavone, preparation method and its as prepare prevention and treatment hepatic injury, the application of cancer drug
CN105198854B (en) * 2015-09-21 2017-05-10 河南中医学院 Preparation method and application of isopentene alkenylation flavonoid compound with nerve protection effect

Also Published As

Publication number Publication date
CN113149944A (en) 2021-07-23
CN108017604A (en) 2018-05-11
CN113149944B (en) 2022-08-05

Similar Documents

Publication Publication Date Title
Shang et al. Antiviral sesquiterpenes from leaves of Nicotiana tabacum
Du et al. Bioactive carbazole alkaloids from the stems of Clausena lansium
Kopa et al. Antiplasmodial anthraquinones and hemisynthetic derivatives from the leaves of Tectona grandis (Verbenaceae)
Yadav et al. Antioxidant furofuran lignans from Premna integrifolia
Shadid et al. Cytotoxic caged-polyprenylated xanthonoids and a xanthone from Garcinia cantleyana
Shen et al. Sesquiterpenes from the leaves of Nicotiana tabacum and their anti-tobacco mosaic virus activity
KITAGAWA et al. Indonesian medicinal plants. VII. Seven new clerodane-type diterpenoids, peronemins A2, A3, B1, B2, B3, C1, and D1, from the leaves of Peronema canescens (Verbenaceae)
Messi et al. Phenolic compounds from the roots of Ochna schweinfurthiana and their antioxidant and antiplasmodial activities
Wu et al. Flavonoids from the seeds of Oroxylum indicum and their anti-inflammatory and cytotoxic activities
Wang et al. Undescribed C-geranylflavonoids isolated from the fruit peel of Paulownia catalpifolia T. Gong ex DY Hong with their protection on human umbilical vein endothelial cells injury induced by hydrogen peroxide
Ma et al. Study of antimalarial activity of chemical constituents from Diospyros quaesita
Kongkum et al. DNA topoisomerase IIα inhibitory and anti-HIV-1 flavones from leaves and twigs of Gardenia carinata
Yeon et al. Three new naphthalenes from the roots of Hibiscus syriacus
CN108017604B (en) Alpha-acid derivative and preparation method and application thereof
Ma et al. Eighteen structurally diversified sesquiterpenes isolated from Pogostemon cablin and their inhibitory effects on nitric oxide production
Zheng et al. Nitric oxide inhibitory coumarins from the roots and rhizomes of Notopterygium incisum
JP2005179339A (en) New compound and medicinal composition
Lin et al. Diarylheptanoids from the fresh pericarps of Juglans hopeiensis
Zhang et al. Thymol derivatives from the roots of Eupatorium chinense and their cytotoxic activities
Ding et al. Phytochemical and pharmacological studies on Chinese changzhu
CN115043792A (en) Achillea millefolium extract, achillea millefolium extract monomer compound, and preparation method and application thereof
Yang et al. Trigochromene A, a new chromane dimer and other components from Trigonostemon howii and their antiproliferative activity
CN113754625B (en) Sesquiterpene coumarin compound and preparation method and application thereof
Willuhn et al. Structure Revision of Xanthalongin and Further Sesquiterpene Lactones from Flowers of Arnica longifolia1
Machado et al. Chalcone–flavone tetramer and biflavones from Aristolochia ridicula

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant